Efgartigimod Treatment Experience in Generalized Myasthenia Gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have a confirmed diagnosis of generalized myasthenia gravis (gMG)
- Have tested positive for AChR antibodies (a blood test that confirms the type of MG)
- Your doctor has already decided to start efgartigimod treatment for you as part of your routine care
- Not currently enrolled in or planning to join another clinical trial with a test medicine
- No severe allergies to the medicine's ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial checks the long-term safety of efgartigimod given through an IV and as a quick under-the-skin injection in children with generalized myasthenia gravis (gMG). It may help your care team understand how safely this treatment can be used over time for kids who already took related study treatments.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
This trial tests if a drug called efgartigimod can help people with generalized myasthenia gravis who have recently had a severe flare-up. Participants will get the drug as maintenance therapy to prevent future crises.
Hear when a new gMG trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.